Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Metzner, Karin J ^a   Leemann, Christine ^a   Di Giallonardo, Francesca ^a   Grube, Christina ^a   Scherrer, Alexandra U ^a   Braun, Dominique ^a   Kuster, Herbert ^a   Weber, Rainer ^a   Guenthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ANEMIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; OUTCOME ASSESSMENT; VIRUS LOAD; CLINICAL TRIAL; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; MUTATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; MALE; MUTATION;

EID: 79960001453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021734     Document Type: Article

References (45)

1. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366: 378-384.
2. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714-720.
3. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
4. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
5. The-UK-Collaborative-Group-on-HIV-Drug-Resistance-and-UK-CHIC-Study-Group (2010) Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy. Clin Infect Dis 50: 1275-1285.
6. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, et al. (2005) Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003. J Acquir Immune Defic Syndr 40: 505-511.
7. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, et al. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-2229.
8. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47: 266-285.
9. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel. JAMA 304: 321-333.
10. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD, (1998) Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 14: 869-876.
11. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, et al. (1999) Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 37: 2291-2296.
12. Metzner KJ, (2006) Detection and significance of minority quasispecies of drug-resistant HIV-1. J HIV Ther 11: 74-81.
13. Heneine W, (2010) When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis 201: 647-649.
14. Gianella S, Richman DD, (2010) Minority Variants of Drug-Resistant HIV. J Infect Dis 202: 657-666.
15. Allers K, Knoepfel SA, Rauch P, Walter H, Opravil M, et al. (2007) Persistence of Lamivudine-Sensitive HIV-1 Quasispecies in the Presence of Lamivudine In Vitro and In Vivo. J Acquir Immune Defic Syndr 44: 377-385.
16. Metzner KJ, Allers K, Rauch P, Harrer T, (2007) Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 21: 703-711.
17. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin Infect Dis 48: 239-247.
18. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, et al. (2001) Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75: 6410-6417.
19. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, et al. (2003) Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188: 1433-1443.
20. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, et al. (2010) Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071.
21. Rieder P, Joos B, von Wyl V, Kuster H, Grube C, et al. (2010) HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 24: 1177-1183.
22. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2008) Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 16: 138-145.
23. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4: e4724.
24. Bergroth T, Ekici H, Gisslen M, Loes SK, Goh LE, et al. (2009) Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naive patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol 81: 1-8.
25. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. (2006) Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells. J Virol 80: 6441-6457.
26. Chun TW, Davey RT Jr, Ostrowski M, Shawn JJ, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti- retroviral therapy. Nat Med 6: 757-761.
27. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, et al. (1999) Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73: 9404-9412.
28. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 105: 16725-16730.
29. Zhang L, Chung C, Hu BS, He T, Guo Y, et al. (2000) Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 106: 839-845.
30. Wainberg MA, (2004) The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2: 147-151.
31. Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, et al. (2003) Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther 8: 51-56.
32. Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, et al. (2003) Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 69: 1-6.
33. Wang J, Bambara RA, Demeter LM, Dykes C, (2010) Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol 84: 9377-9389.
34. Coffin JM, (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
35. Metzner KJ, (2006) Persistence of drug-resistant HIV-1 and possible implications for antiretroviral therapy. Future Virology 1: 377-391.
36. Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, et al. (2007) No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 39: 43-47.
37. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
38. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, et al. (2010) Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE 5: e10952.
39. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, et al. (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201: 662-671.
40. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment Outcomes. J Infect Dis 199: 693-701.
41. Vignoles M, Barboni G, Agosti MR, Quarleri J, Garcia MK, et al. (2009) Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antivir Ther 14: 1175-1181.
42. Balduin M, Oette M, Daumer MP, Hoffmann D, Pfister HJ, et al. (2009) Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure. J Clin Virol 45: 34-38.
43. Carr JM, Green T, Shaw D, Daly L, Hart W, et al. (2009) Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naive and experienced patients. J Med Virol 81: 1983-1990.
44. Jakobsen MR, Tolstrup M, Sogaard OS, Jorgensen LB, Gorry PR, et al. (2010) Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome. Clin Infect Dis 50: 566-573.
45. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22: 1417-1423.